Cabaletta Bio Reports Third Quarter 2022 Financial Results and Provides Business Update
PHILADELPHIA, Nov. 10, 2022 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq:CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today reported financial results for the third quarter ended September 30, 2022, and provided a business update.
Related news for (CABA)
- Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress
- Today’s Top Performers: MoBot’s Market Review 10/09/25 12:00 PM
- 24/7 Market News Snapshot 09 October, 2025 – Cabaletta Bio, Inc. Common Stock (NASDAQ:CABA)
- MoBot’s Stock Market Highlights – 08/13/25 03:00 PM
- Today’s Top Performers: MoBot’s Market Review 08/13/25 11:00 AM